Consensus report: indications for use of long-acting antimuscarinic tiotropium in the treatment of bronchial asthma
https://doi.org/10.18093/0869-0189-2015-25-2-143-150
Abstract
Relevant indications for tiotropium Respimat in adult patients with bronchial asthma (BA) were reviewed. This consensus represents a collaborative effort of members of the Executive Group of Russian Respiratory Society. The Group consisted of clinicians, pharmacologists and researchers with recognized expertise in therapeutic field. The draft of the recommendations was prepared by initiative group. Each point of the recommendation was discussed during Executive group meeting and was accepted by vote of majority members. Final version of the consensus statement was approved by each member of Executive group. As concluded, tiotropium Respimat could be recommended for adult patients with bronchial asthma as: 1) add-on therapy in patients with severe and moderate severe non-controlled BA on GINA step 3–5 (ICS and LABA, including oral steroids or other controllers, or high doses ICS monotherapy); 2) add-on therapy in patients with asthma-COPD overlap syndrome (ACOS); 3) add-on therapy to ICS in case of side effects, contraindications for use or individual intolerance of LABA; 4) additional indications to consider use of tiotropium Respimat may include: smoking, positive SABA reversibility test, predominant nocturnal asthma symptoms.
About the Authors
A. G. ChuchalinRussian Federation
MD, Professor, Academician of the Russian Science Academy, Director of Federal State Budget institution «Pulmonology Research Institute», Federal Medical and Biological Agency of Russia, the Chairman of the Russian Respiratory Society, Chief Therapeutist and Pneumologist of the Healthcare Ministry of Russian Federation; tel.: (495) 465-52-64;
S. N. Avdeev
Russian Federation
MD, Professor, Head of Clinical Department, Federal State Federal Institution «Pulmonology Research Institute», Federal Medical and Biological Agency of Russia; tel.: (495) 465-52-64
Z. R. Aisanov
Russian Federation
MD, Professor, Head of Department of Clinical Physiology and Clinical Trials, Federal State Budget institution «Pulmonology Research Institute», Federal Medical and Biological Agency of Russia, tel.: (495) 965-34-66;
V. V. Arkhipov
Russian Federation
MD, Professor, State Institution "I.M.Sechenov First Moscow State Medical University", Healthcare Ministry of Russia; tel.: +7-985-190-17-00
A. S. Belevskii
Russian Federation
MD, Professor of Department of Pulmonology, Faculty of Postgraduate Physician Training, State Institution "N.I.Pirogov Russian National Research Medical University", Healthcare Ministry of Russia; tel.: (495) 963-24-67;
N. M. Nenasheva
Russian Federation
MD, Professor of Chair of Clinical Allergology, State Budget Educational Institution of Аdditional Еducation "Russian Medical Postgraduate Academy", Healthcare Ministry of Russia, tel.: (499) 196-17-86;
References
1. Архипов В.В., Григорьева Е.В., Гавришина Е.В. Контроль над бронхиальной астмой в России: результаты многоцентрового наблюдательного исследования НИКА. Пульмонология. 2011; 6: 87–93. / Arkhipov V.V., Grigor'eva E.V., Gavrishina E.V. Asthma control in Russia: results of the multicenter observational study NIKA. Pul'monologiya. 2011; 6: 87–93 (in Russian).
2. Braman S.S. The global burden of asthma. Chest 2006; 130 (1, Suppl.): 4–12.
3. Rodrigo G.J., Castro-Rodríguez J.A. What is the role of tiotropium in asthma? A systematic review with meta-analysis. Chest. 2015; 147 (2): 388–396. DOI: 10.1378/chest.14-1698.
4. Fardon T., Haggart K., Lee D.K, Lipworth BJ. A proof of concept study to evaluate stepping down the dose of fluticasone in combination with salmeterol and tiotropium in severe persistent asthma. Respir. Med. 2007; 101: 1218–1228.
5. Peters S.P., Kunselman S.J., Icitovic N. еt al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N. Engl. J. Med. 2010; 363 (18): 1715–1726.
6. Bateman E.D., Kornmann O., Schmidt P. et al. Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma. J. Allergy Clin. Immunol. 2011; 128 (2): 315–322.
7. Kerstjens H.A., Disse B., Schr#öder-Babo W. et al. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. J. Allergy Clin. Immunol. 2011; 128 (2): 308-14.
8. Kerstjens H.A., Engel M., Dahl R. et al. Tiotropium in asthma poorly controlled with standard combination therapy. N. Engl. J. Med. 2012; 367 (13): 1198–1207.
9. http://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview/clinical_trial_result.c=i.i=6.html
10. Vogelberg C., Engel M., Moroni-Zentgraf P. et al. Tiotropium in asthmatic adolescents symptomatic despite inhaled corticosteroids: a randomised dose-ranging study. Respir. Med. 2014; 108 (9): 1268–1276.
11. Beeh K.-M., Moroni-Zentgraf P., Ablinger O. et al. Tiotropium Respimat in asthma: a double-blind, randomised, dose-ranging study in adult patients with moderate asthma. Respir. Res. 2014, 15: 61.
12. Kerstjens H.A., Disse B., Schr#öder-Babo W. et al. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. J. Allergy. Clin. Immunol. 2011; 128 (2): 308–314.
13. Global Strategy for Asthma Management and Prevention. Revised 2014. www.ginasthma.com
14. Iwamoto H., Yokoyama A., Shiota N. et al. Tiotropium bromide is effective for severe asthma with noneosinophilic phenotype. Eur. Respir. J. 2008; 31: 1379–1382.
15. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Revised 2014. www.goldcopd.com
16. de Marco R., Pesce G., Marcon A. et al. The coexistence of asthma and chronic obstructive pulmonary disease (COPD): Prevalence and risk factors in young, middle-aged and elderly people from the general population. PLoS ONE. 2013; 8 (5): e62985. DOI:10.1371/journal.pone.0062985.
17. Diagnosis of Diseases of Chronic Airflow Limitation: Asthma, COPD and Asthma-COPD Overlap Syndrome (ACOS). http://www.ginasthma.org
18. Soler-Catalu#ña J.J., Cos#ío B., Izquierdo J.L. Consensus document on the overlap phenotype COPD – asthma in COPD. Arch. Bronconeumol. 2012; 48 (9): 331–337.
19. Magnussen H., Bugnas B., van Noord J. et al. Improvements with tiotropium in COPD patients with concomitant asthma. Respir. Med. 2008; 102: 50–56.
20. Magnussen H., Bugnas B., van Noord J. et al. COPD and concomitant asthma: Efficacy of tiotropium in different age, PEFR variability and bronchodilator responsiveness groupings. ATS International Conference; 2008: Abs.649.
21. Yoshida M., Nakano T., Fukuyama S. et al. Effects of tiotropium on lung function in severe asthmatics with or without emphysematous changes. Pulm. Pharmacol.Ther. 2013; 26: 159–166.
22. Catterall J.R., Rhind G.B., Whyte K.F. et al. Is nocturnal asthma caused by changes in airway cholinergic activity? Thorax. 1988; 43: 720–724.
23. Coe C.I., Barnes P.J. Reduction of nocturnal asthma by an inhaled anticholinergic drug. Chest. 1986; 90: 485–488.
24. Cox I.D., Hughes D.T., McDonnell K.A. Ipratropium bromide in patients with nocturnal asthma. Postgrad Med. J. 1984; 60: 526–528.
25. McNicholas W.T., Calverley P.M.A., Lee A. et al. Long-acting inhaled anticholinergic therapy improves sleeping oxygen saturation in COPD. Eur. Respir. J. 2004; 23: 825–831.
26. Di Lorenzo G., Mansueto P., Ditta V. et al. Similarity and differences in elderly patients with fixed airflow obstruction by asthma and by chronic obstructive pulmonary disease. Respir. Med. 2008; 102 (2): 232–238.
27. Peters S.P., Bleecker E.R., Kunselman S.J. et al. Predictors of response to tiotropium versus salmeterol in asthmatic adults. J. Allergy Clin. Immunol. 2013; 132 (5): 1068–1074.
28. ten Brinke A., Zwinderman A.H., Sterk P.J. et al. Factors associated with persistent airflow limitation in severe asthma. Am. J. Respir. Crit. Care Med. 2001; 164: 744–748.
29. Busacker A., Newell J.D. Jr., Keefe T. et al. A multivariate analysis of risk factors for the air-trapping asthmatic phenotype as measured by quantitative CT analysis. Chest. 2009; 135: 48–56.
30. O’Donnell D.E., Fluge T., Gerken F. et al. Effects of tiotropium on lung hyperinflation, dyspnea and exercise tolerance in COPD. Eur. Respir. J. 2004; 23: 832–840.
31. Bedard M.E., Brouillard C., Pepin V. et al. Tiotropium improves walking endurance in COPD. Eur. Respir. J. 2012; 39: 265–271.
32. Feschenko Y., Yashyna L., Gorovenko N. et al. Influence of combined antiasthmatic basic therapy on hyperinflation in patients with severe bronchial asthma. Eur. Respir. J. 2007; 30 (Suppl.): 553–554.
33. Miota J., Barbara C., Cardoso J. et al. Tiotropium improves FEV1 in patients with COPD irrespective of smoking status. Pulm. Pharmacol. Ther. 2008; 21 (1): 146–151.
34. Ahmad Z., Singh S.K. Relative and additional bronchodilator response of salbutamol and ipratropium in smoker and nonsmoker asthmatics. J. Asthma. 2010; 47 (3): 340–343.
35. Rebordosa C., Kogevinas M., Guerra S. et al. ADRB2 Gly16Arg polymorphism, asthma control and lung function decline. Eur. Respir. J. 2011; 38 (5): 1029–1035.
36. Park H.W., Yang M.S., Park C.S. et al. Additive role of tiotropium in severe asthmatics and Arg16Gly in ADRB2 as a potential marker to predict response. Allergy. 2009; 64: 778–783.
Review
For citations:
Chuchalin A.G., Avdeev S.N., Aisanov Z.R., Arkhipov V.V., Belevskii A.S., Nenasheva N.M. Consensus report: indications for use of long-acting antimuscarinic tiotropium in the treatment of bronchial asthma. PULMONOLOGIYA. 2015;25(2):143-150. (In Russ.) https://doi.org/10.18093/0869-0189-2015-25-2-143-150
Views:
1533
Email this article 